Clinical trials: Tumor Markers, Biological
Clear Cell Renal Cell Carcinoma
Diagnostic Imaging for Clear Cell Renal Cell Carcinoma
The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype.
- Trial name
- RCCSCAN (NCT03185182)
- Testing
- Ioflupane I123
- Where
- Sweden
- Volunteers
- 5 people
- Sponsor
- Region Skane
Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
To explore the effectiveness and safety of adebrelimab combined with chemotherapy and concurrent SBRT for 3 cycles of neoadjuvant treatment followed by surgery in T1-3N0-1M0 limited-stage SCLC
- Trial name
- Neoadjuvant (NCT06562920)
- Testing
- adebrelimab and chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation
The purpose of this study is to determine whether genetic markers unique to liver cancer are present and to assess usefulness as a diagnostic tool.
- Trial name
- NCT02412579
- Testing
- None - Standard of Care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Baylor Research Institute
Colorectal Cancer
Ancillary Study of Methylation Biomarkers in a Randomized Controlled Trial of a Personalized Prevention of Colorectal Cancer
Based on the magnesium tolerance test (MTT, "gold standard" for assessing magnesium (Mg) status), it was found that over 50% of participants in the US exhibited Mg deficiency.
- Trial name
- NCT04196803
- Testing
- Magnesium glycinate
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Oropharyngeal Cancer, HPV-Related Carcinoma
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
Investigators seek to determine the sensitivity and specificity of a combined HPV 16 DNA and host gene methylation oral biomarker panel to distinguish early Oropharyngeal Cancer (OPC) cases from controls among 100 early and 100…
- Trial name
- BASH OPC (NCT06305676)
- Testing
- combined HPV 16 DNA and host gene methylation oral biomarker panel
- Where
- 3 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Colorectal Cancer
Specimens for Septin 9 Performance
Epigenomics has identified methylated gene regions that are specific for colorectal cancer (CRC). Through Epigenomics' marker discovery and validation process Septin 9 was identified as a particularly robust methylation marker…
- Trial name
- SPR0012 (NCT01329718)
- Testing
- Blood Sample
- Volunteers
- 562 people, healthy volunteers welcome
- Sponsor
- Epigenomics, Inc
Lung Cancer, Non-small Cell Lung Cancer Stage I
Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer
The goal of this prospective, case-control study is to discover the specific "omics" biomarkers of early stage of lung cancer using the non-invasive samples (breath, urine and serum) in a total of 200 subjects (100 healthy…
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Lung Cancer Diagnosis
- Trial name
- NCT06341387
- Testing
- Breath, urine and blood analysis
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to determine the activity of tamibarotene in participants with relapsed/refractory (R/R) AML (administered as a monotherapy or in combination with azacitidine), R/R higher-risk MDS (HR-MDS)…
- Trial name
- NCT02807558
- Testing
- Tamibarotene, Azacitidine, Daratumumab
- Where
- 26 sites in United States, France
- Volunteers
- 155 people
- Sponsor
- Syros Pharmaceuticals
Doxorubicin Adverse Reaction, Cardiomyopathies, Secondary
The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor
This study looks to find a causative or predictive aspect of the suPAR biomarker for heart failure in breast cancer patients receiving Doxorubicin drug chemo regimen.
- Conditions
- Doxorubicin Adverse Reaction, Cardiomyopathies, Secondary, Breast Cancer
- Trial name
- NCT03505164
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Rush University Medical Center
NSCLC (Non-small Cell Lung Cancer), Hyperprogression
Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial
In metastatic NSCLC patients with PD-L1 expression ≥50%, a circulating immature (CD10-) LDNs level of ≥30.5% confers a high risk of hyperprogression (HPD) with first line single-agent immune-checkpoint inhibitors (SA-ICI).
- Trial name
- HYPERBOLIC (NCT07274384)
- Testing
- chemotherapy plus cemiplimab, Cemiplimab
- Volunteers
- 74 people
- Sponsor
- Università Vita-Salute San Raffaele
Neuroblastoma, Central Nervous System Tumors
Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas
Studies have provided evidence that residual microscopic malignant cells in autologous bone marrow or blood stem cell grafts can contribute to posttransplant relapse.
- Conditions
- Neuroblastoma, Central Nervous System Tumors, Lymphomas, Wilms Tumor
- Trial name
- NCT00152126
- Testing
- Stem Cell Transplantation, Busulfan, Melphalan
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- St. Jude Children's Research Hospital
Non-small Cell Lung Cancer
A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers
PFS
- Trial name
- NCT01860508
- Testing
- pemetrexed /carboplatin
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Fudan University
Melanoma
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
- Trial name
- NCT03727087
- Testing
- Blood Sample Collection
- Where
- 36 sites in United States
- Volunteers
- 348 people
- Sponsor
- Exact Sciences Corporation
Cancer, Metastatic Cancer
Biomarkers of Immune-Related Toxicity
This is a single-center, correlative pilot study evaluating potential biomarkers predictive of immune-related adverse events associated with immune checkpoint inhibitor therapy.
- Trial name
- NCT03409016
- Testing
- Blood Testing
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Colorado, Denver
Metastatic Kidney Cancer, Metastatic Renal Cell Carcinoma
Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer
One third of patients with kidney cancer are diagnosed in the metastatic stage, and among patients with a localized form, about 30 to 40% will develop metastases after surgery.
- Trial name
- CA9CRM (NCT00942058)
- Testing
- Serum and urinary CA9 level
- Where
- 3 sites in France
- Volunteers
- 16 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Prostate Cancer
Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
This is a multicenter, Phase II randomized biomarker-based therapeutic study in metastatic prostate cancer experiencing prostate specific antigen (PSA) only progression (without visceral, bone or lymph node progression) while on…
- Trial name
- NCT05705700
- Testing
- Dutasteride, Abiraterone
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bladder Cancer
Detection of K14 in Bladder Cancer With a Non Invasive Technique
By an invasive technique keratin 14 has been identified as a prognostic factor in bladder cancer. This study aims to analyze whether through a non-invasive technique keratin 14 can be used as a diagnostic and prognostic marker…
- Trial name
- NCT02027649
- Where
- Spain
- Volunteers
- 400 people
- Sponsor
- Corporacion Parc Tauli
Oral Cancer
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
Surgical resection followed by concurrent chemoradiotherapy is considered as the standard of care for locally advanced OSCC (LAOSCC).
- Trial name
- NCT00933387
- Testing
- Cetuximab,Paclitaxel,Cisplatin
- Where
- Taiwan
- Volunteers
- 47 people
- Sponsor
- National Health Research Institutes, Taiwan
Acute Myeloid Leukemia
Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers
In this open-label, single-center, non-randomized patients with AML (Acute Myeloid Leukemia) and receiving all induction chemotherapy and consolidation consisting of cytarabine under the care usual for this pathology, will be…
- Trial name
- NCT03337516
- Testing
- Blood sampling, Genetic analysis
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Breast Neoplasm Female, Ultrasound Therapy; Complications
Mayo Designed Soft Tissue Ultrasound-Detectable Marker
Researchers are trying to determine if the Mayo marker is easily seen with ultrasound making it easier, faster, and more accurate for preoperative localization of the biopsied positive lymph node.
- Trial name
- NCT04674852
- Testing
- Research Marker
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.